Table of Contents
Building a biopharmaceutical company committed to...
Safe Harbor Statement
Amylin Pharmaceuticals, Inc. Uniquely Positioned to Build a Franchise in Metabolic Diseases
2002 Achievements
Corporate Strategy
Corporate Strategy
Corporate Strategy
SYMLIN™ (pramlintide acetate) Potential Complementary Therapy to Insulin
SYMLIN™ (pramlintide acetate) Unique Profile in Type 1 and Type 2 Diabetes
SYMLIN™ Regulatory Status
SYMLIN™ Market Opportunity United States
SYMLIN™ Market Opportunity United States
SYMLIN™ Commercial Plans United States
AC2993 (exenatide) Potential Treatment for Type 2 Diabetes
AC2993 Market Opportunity United States
AC2993 28-Day Profile in Type 2 Diabetes Potent Glucose-Lowering with No Weight Gain
AC2993 Global Collaboration with Eli Lilly and Company
AC2993 Program Update
AC2993 12-Week Profile in Type 2 Diabetes Open-label Data Show Progressive Reductions in HbA1c
AC2993 LAR Goal: Sustained-Release Treatment for Type 2 Diabetes
Corporate Strategy
Cardiovascular Disease Building on Our Strengths
Obesity Building on Our Strengths
Amylin Product Pipeline Summary
Management Experience and Expertise
Financial Overview
Milestones
Amylin Pharmaceuticals, Inc. Uniquely Positioned to Build a Franchise in Metabolic Diseases
|